Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: a Swedish single center experience

Table 3 Univariate and multivariate Cox proportional hazard regression evaluating the risk of endpoint (death or heart transplantation) in the entire cohort

	Univariate	Multivariate
	p	Model 1 N patients = 72 N events = 23		Model 2 N patients = 71 N events = 23		Model 3 N patients = 65 N events = 20
	p	HR [CI]	P	HR [CI]	P	HR [CI]	P
Baseline characteristics
Age (years)	0.564
Male gender	0.004	3.11 [1.20–8.05]	0.019	4.11 [1.65–10.23]	0.002	2.84 [0.98–8.26]	0.055
BMI (kg/m²)	0.151
GCM diagnosis	< 0.001	3.61 [1.42–9.21]	0.007	3.47 [1.37–8.79]	0.009	2.69 [0.81–8.94]	0.106
NT-proBNP (pg/L)	< 0.001					1.00 [1.00–1.00]	0.259
eGFR (ml/min/1.73 m²)	0.008
NYHA class ≥ III	< 0.001			3.38 [1.13–10.12]	0.03
Prevalent clinical cardiac manifestations
Heart failure	0.094
Sustained VT or cardiac arrest	0.576
High-grade AVB	0.06
Echocardiography findings
LV EF (%)	< 0.001	0.95 [0.91–0.99]	0.01
RV dyfunction	0.005	1.29 [0.47–3.56]	0.627	1.67 [0.64–4.35]	0.293	2.39 [0.82–7.05]	0.06

AVB, atrio-ventricular block; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; GCM, giant cell myocarditis; HR, hazard ratio; LV EF, left ventricle ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type; RV, right ventricular; VT, ventricular tachycardia

ISSN: 1471-2261